11:30 , Jun 5, 2018 |  BC Extra  |  Company News

Zai Lab names Liang as first CCO

Zai Lab Ltd. (NASDAQ:ZLAB) announced William Liang has joined the Chinese biotech as its first chief commercial officer. Liang has over 20 years of experience running commercial operations for pharma in China. He was previously...
19:41 , Apr 14, 2017 |  BC Week In Review  |  Company News

General Electric, Zai Lab deal

The GE Healthcare unit of General Electric and Zai Lab partnered to build the Zai Lab - GE Biotherapeutics Development & Manufacturing/Processing Demonstration Site for the production of Zai biologics. The site will include GE...
17:01 , Dec 14, 2016 |  BioCentury  |  Finance

Zai’s supportive investments

Zai Lab Ltd. has taken a rare step for a young company by deciding to use some of its VC-raised cash to invest in other life science companies. According to Chairman and CEO Samantha Du,...
08:00 , Nov 2, 2015 |  BioCentury  |  Strategy

Zai's second act

When Zai Laboratory Ltd. first launched in 2013, its immediate plan was to in-license programs from companies and academics in the West and Asia. Now with five licensed programs under its belt, the biotech is...
01:49 , Oct 24, 2015 |  BC Extra  |  Company News

Zai moves into drug discovery

Zai Laboratory Ltd. (Shanghai, China) opened an R&D center in Shanghai and announced a discovery and development partnership with Tsinghua University Immunology Institute. The moves expand the company's business model beyond in-licensing therapeutics that target...
01:29 , Sep 23, 2015 |  BC Extra  |  Company News

Zai licenses UCB's preclinical autoimmune compound

UCB Group (Euronext:UCB) granted Zai Laboratory Ltd. (Shanghai, China) an exclusive, worldwide license to develop and commercialize a preclinical mAb in all indications, including autoimmune diseases such as graft-versus-host disease (GvHD) and inflammatory bowel disease...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Company News

Bristol-Myers Squibb Co, Zai Laboratory deal

Bristol-Myers granted Zai exclusive rights to develop, commercialize and manufacture oral brivanib in China, including Hong Kong and Macau, for oncology indications. BMS discontinued global development of brivanib in 2012 after it missed the...
01:54 , Mar 24, 2015 |  BC Extra  |  Company News

Zai gains China rights to BMS's brivanib

Bristol-Myers Squibb Co.(NYSE:BMY) granted Zai Laboratory Inc. (Shanghai, China) exclusive rights in China, including Hong Kong and Macau, to oral brivanib to treat oncology indications including hepatocellular carcinoma (HCC). The compound is a dual inhibitor...
07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...